Nevada has been relatively active in the most recent legislative term on healthcare price transparency, costs, and markets. Nevadas primary effort in healthcare transparency and cost containment in 2017 was the Nevada Care Plan, which would have allowed anyone without health insurance buy into the states Medicaid program. Because of Medicaids low reimbursement rates for doctors and other health-care providers, it may have provided an economical alternative to private insurance, though at the cost of narrower provider options. The bill creating this new Medicaid buy-in cleared the legislature, but was vetoed by Republican Governor Brian Sandoval.Nevada also gained widespread attention as the first state to target medicines for a specific ailment, passing SB 539 which requires more transparency from drug makers over their pricing of diabetes medicines. The pharmaceutical industry pushed back with a lawsuit claiming the transparency law is unprecedented and unconstitutional, because it interferes with well-established patent law by robbing drug makers of their right to protect trade secrets. The case is outstanding in Nevada District Court.